Richard R Schmidt

This inventor holds 17 USPTO granted patents and 2 EPO patents, primarily in Glycosylation Chemistry. Top assignees: Ludwig Institute for Cancer Research Limited, Basf Aktiengesellschaft, Solco Basel Ag. Active years: 1988-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard R Schmidt. Retrieved from https://idiyas.com/inventor/richard-r-schmidt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17

% Patents Active = 70.6

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 134(Granted Patents)

Location History:

Constance, DE (1988 - 2012)
Konstanz, DE (1990 - 2012)

Company Filing History:

7 out of 531

Ludwig Institute for Cancer Research Limited

patents

5 out of 10,816

Basf Aktiengesellschaft

Oxford University Innovation Ltd

patents

5. 2 out of 519

Sloan-Kettering Institute for Cancer Research

patents

6. 2 out of 125

The University of Birmingham

patents

7. 1 out of 1,248

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

8. 1 out of 834,708

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2012

Loading Chart...

Areas of Expertise:

Alpha Galactosylceramide

Chelators

Glycoproteins

Carbohydrate Derivatives

GM3 Synthesis

GM2 Synthesis

Alkyl Glycosides

Sphingosine Derivatives

Bisglycosides

Pharmaceutical Products

Solid-Phase Synthesis

Stereoselective Preparation

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8334408 - Analogs of alpha galactosylceramide and uses thereof (2012-12-18),

2. 8188313 - Analogs of alpha galactosylceramide and uses thereof (2012-05-29),

3. 8173102 - Tame based chelators and uses thereof (2012-05-08),

4. 8039670 - Analogs of alpha galactosyceramide and uses thereof (2011-10-18),

5. 7780947 - Tame based chelators and uses thereof (2010-08-24),

6. 6692931 - Recombinant glycoproteins, method for the production thereof, medicaments containing said glycoproteins and use thereof (2004-02-17),

7. 6242583 - Carbohydrate derivatives and their solid-phase synthesis (2001-06-05),

8. 5977329 - Methods of synthesizing GM3 (1999-11-02),

9. 5756695 - Methods of synthesizing GM2 (1998-05-26),

10. 5739301 - 1-(2'-hydroxy and 2'-sulfatoalkyl) glycoside (1998-04-14),

11. 5498704 - Preparation of alkyl glycosides (1996-03-12),

12. 5371203 - Process for the stereoselective preparation of .beta.-fucopyranosyl (1994-12-06),

13. 5126441 - Bisglycosides (1992-06-30),

14. 5010059 - Pharmaceutical products and lactosyl compounds (1991-04-23),

15. 4952683 - Process for the preparation of sphingosine derivatives (1990-08-28),

Title: Richard R. Schmidt: Innovator in Cancer Research

Introduction

Richard R. Schmidt is an accomplished inventor based in Constance, Germany, renowned for his significant contributions to the field of cancer research. With a remarkable portfolio of 17 patents, he has dedicated his career to advancing scientific understanding and treatment options.

Latest Patents

Among his latest innovations are the patents for "Analogs of alpha galactosylceramide and uses thereof - Compounds of formula." These patents address novel compounds that hold promise for improving therapeutic approaches in cancer treatment, highlighting his ongoing commitment to medical advancement.

Career Highlights

Throughout his career, Richard has garnered extensive experience in reputable organizations, including the Ludwig Institute for Cancer Research and BASF Aktiengesellschaft. His work in these institutions has allowed him to contribute to groundbreaking research and develop innovative solutions in the realm of oncology.

Collaborations

Richard has had the opportunity to collaborate with notable colleagues such as Gerd J. Ritter and Vincenzo Cerundolo. These collaborations have fostered a dynamic exchange of ideas and expertise, further enriching his contributions to the scientific community.

Conclusion

In conclusion, Richard R. Schmidt stands out as a prominent figure in the intersection of innovation and cancer research. His patents and collaborative efforts continue to push the boundaries of scientific inquiry, making a significant impact on the future of medical treatments.

Profile summary based on public USPTO records.